Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Last trade$120.58
Day change-$0.76 (-0.63%)
Day range$117.14 – $122.64
Volume258,123
Market cap$5.53B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.53B
Price / earnings
53.18×
Price / book
6.15×
Price / sales
4×
EV / sales
4.62×
EV / EBITDA
17.75×
Profitability
Earnings per share
$2.28
Return on assets
4.31%
Return on equity
11.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.25×
Current ratio
2.84×
Quick ratio
1.83×
Cash ratio
0.87×
Cash flow
Price / cash flow
16.02×
Price / free cash flow
20.06×
Free cash flow
$275.5M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for HAE, quarterly periods
Line item
Q2 FY2027 Sep 26, 2026
Q1 FY2027 Jun 27, 2026
Q4 FY2026 Mar 28, 2026
Q3 FY2026 Dec 27, 2025
Q2 FY2026 Sep 27, 2025
Q1 FY2026 Jun 28, 2025
Q4 FY2025 Mar 29, 2025
Q3 FY2025 Dec 28, 2024
Revenue
$357.76M
$339.38M
$346.35M
$338.97M
$327.32M
$321.39M
$330.6M
$348.54M
Cost of revenue
$147.25M
$136.58M
$148.14M
$136.58M
$143.75M
$129.15M
$137.55M
$155M
Gross profit
$210.51M
$202.8M
$198.21M
$202.39M
$183.56M
$192.24M
$193.05M
$193.55M
Selling, general and administrative
$118.36M
$118.94M
$120.93M
$109.15M
$101.62M
$110.72M
$115.14M
$106.46M
Research and development
$17.03M
$16.2M
$14.45M
$14.19M
$14.87M
$16.26M
$18.31M
$15.83M
Total operating expenses
$135.39M
$145.35M
$221.24M
$134.99M
$125.07M
$138.37M
$121.72M
$134.52M
Operating income
$75.12M
$57.46M
-$23.03M
$67.4M
$58.49M
$53.87M
$71.34M
$59.03M
Interest expense
-$12.26M
-$9.88M
$0
$0
-$7.21M
-$8.7M
$0
$0
Income before taxes
$62.86M
$47.57M
-$28.4M
$59.98M
$51.29M
$45.17M
$70.74M
$49.92M
Income taxes
$16.55M
$14.56M
-$8.25M
$15.24M
$12.6M
$11.14M
$12.76M
$12.42M
Net income
$46.31M
$33.01M
-$20.15M
$44.74M
$38.68M
$34.03M
$57.98M
$37.49M
Net income attributable to common shareholders
$46.31M
$33.01M
-$20.15M
$44.74M
$38.68M
$34.03M
$57.98M
$37.49M
EBITDA
$102.88M
$84.57M
$75.73M
$96.82M
$95.33M
$82.63M
$87.22M
$91.4M
Basic earnings per share
$1.02
$0.73
-$0.44
$0.96
$0.81
$0.71
$1.18
$0.75
Diluted earnings per share
$1.00
$0.72
-$0.43
$0.95
$0.81
$0.70
$1.17
$0.74
Recent news
Company coverage with links to the original publishers.
Haemonetics (HAE) reported quarterly earnings of $1.35 per share, beating consensus estimates of $1.30, with revenues of $357.76 million exceeding expectations by 3.15%. The company has outperformed market estimates in four consecutive quarters and gained 59% year-to-date. However, the Medical-Products industry ranks in the bottom 36% of Zacks industries, which could limit future performance despite HAE's Zacks Rank #2 (Buy) rating.
In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) and Haemonetics (HAE), both holding a Zacks Rank #2 (Buy), GEHC emerges as the superior value option. GEHC has a lower forward P/E ratio of 15.33 compared to HAE's 22.35, a better PEG ratio of 2.00 versus 2.37, and a more favorable P/B ratio of 2.94 versus 6.42, earning it a Value grade of B compared to HAE's C grade.
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The company, which provides blood management systems, is positioned in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential near-term stock price appreciation.
Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.
Haemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.